Allergy Attack Relief to Go

Manufacturer: Breakthrough Products Inc.
Effective date: 2014-10-09
Label type: HUMAN OTC DRUG LABEL
Version: 4
Source: full-release
Hydrated at: 2026-05-31 22:40:33

Label at a glance#

ProductAllergy Attack Relief to Go

Active ingredientDIPHENHYDRAMINE HYDROCHLORIDE

Label structure10 sections

Indications and uses

Temporarily relieves these symptoms due to hay fever and other upper respiratory allergies: runny nose itchy, watery eyes sneezing itching of the nose and throat Temporarily relieves these symptoms due to common cold: runny nose sneezing

Dosage and administration

adults and children 12 years and over: see instructions in red box for opening packet place 25mg (1 powder) to 50mg (2 powders) on the tongue and swallow with or without water take every 4 to 6 hours do not take more than 300mg (12 powders) in 24 hours children 6 to under 12 years of age: place 12.5mg (this dose strength is not available in this package) to 25mg (1 powder) on the tongue and swallow with or without...

Contacts and useful links#

PhoneLabel contact1-888-998-7436

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Drug Facts

Active ingredient (per powder)

OTC - ACTIVE INGREDIENT SECTION

Diphenhydramine HCl 25mg

Purpose

OTC - PURPOSE SECTION

Antihistamine

Uses

INDICATIONS & USAGE SECTION

Temporarily relieves these symptoms due to hay fever and other upper respiratory allergies:

runny nose
itchy, watery eyes
sneezing
itching of the nose and throat

Temporarily relieves these symptoms due to common cold:

runny nose
sneezing

Warnings

WARNINGS SECTION

OTC - DO NOT USE SECTION

Do not use with any other product containing diphenhydramine, even one used on skin.

Ask a doctor before use if you have

OTC - ASK DOCTOR SECTION

glaucoma
a breathing problem such as emphysema or chronic bronchitis
trouble urinating due to an enlarged prostate gland

OTC - ASK DOCTOR/PHARMACIST SECTION

Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers.

When using this product

OTC - WHEN USING SECTION

marked drowsiness may occur
avoid alcoholic drinks
alcohol, sedatives, and tranquilizers may increase drowsiness
be careful when driving a motor vehicle or operating machinery
excitability may occur, especially in children

OTC - PREGNANCY OR BREAST FEEDING SECTION

If pregnant or breast-feeding, ask a health professional before use.

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. Do not use to make a child sleepy.

Directions

DOSAGE & ADMINISTRATION SECTION

adults and children 12 years and over:

see instructions in red box for opening packet
place 25mg (1 powder) to 50mg (2 powders) on the tongue and swallow with or without water
take every 4 to 6 hours
do not take more than 300mg (12 powders) in 24 hours

children 6 to under 12 years of age:

place 12.5mg (this dose strength is not available in this package) to 25mg (1 powder) on the tongue and swallow with or without water
take every 4 to 6 hours
do not take more than 150mg (6 powders) in 24 hours
do not attempt to divide a powder in half

children under 6 years of age: do not use

Inactive ingredients

INACTIVE INGREDIENT SECTION

citric acid, ethylcellulose, flavor, glucose, hydroxypropyl cellulose, starch, sucralose, sucrose

Questions?

OTC - QUESTIONS SECTION

1-888-998-7436 (Mon-Fri 9AM-5PM MDT)

SPL UNCLASSIFIED SECTION

Do not use if pouch
is torn or open

distributed by
URGENT Rx®
Breakthrough Products, Inc.
Denver, CO 80202

PRINCIPAL DISPLAY PANEL - 1 Powder Packet

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

New!

NO
WATER
REQUIRED
POUR DIRECTLY IN MOUTH

URGENT Rx^®
FAST
POWDERS _™

SEE OPENING INSTRUCTIONS ON BACK PANEL

ALLERGY
ATTACK

URGENT Rx^®

RELIEF
TO-GO_™

DIPHENHYDRAMINE HCl /
ANTIHISTAMINE

raspberry

distributed by UrgentRx
1 POWDER PACK

Principal Display Panel - 1 Powder Packet

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	SPL version
1312784	diphenhydrAMINE HCl 25 MG Oral Powder	PSN	4
1312784	diphenhydramine hydrochloride 25 MG Oral Powder	SCD	4

DailyMed Pharmacologic Classes#

Class, Version, Type table
Class	Version	Type	Effective
DIPHENHYDRAMINE Pharmacologic Class Indexing	3	Indexing - Pharmacologic Class	20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
0e2e0f88-b076-afe1-4bdd-32bca4375bec	Product name	3	20250127
e2db08c6-133f-4f4f-afb4-e90a2418d6f6	Product name	1	20230320
ce6d5c06-3ae0-18a6-d5b3-8cd3cc0f8906	Product name	7	20210625
f52be47f-7aa7-46c0-b1fa-50c18dd50206	Product name	1	20201029
11ed6f83-cdd2-4637-8379-b1a1d3ae3cde	Product name	1	20181101
86c45a79-b9f0-4476-a27c-6e10db098497	Product name	1	20180125
d5e51f11-ad28-caa4-4b49-4143974782ad	Product name	1	20150831
3e48c9c4-918d-5d23-2f0b-d2398b06be54	Product name	1	20140508
865c72dd-0d94-daac-f728-ddd4ded2a79e	Product name	1	20140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3	Product name	1	20140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDC	Effective	Action	Document	Indexing SPL	Related label
51596-009-01	2020-01-31	C162847	48780-1	9d75b9cf-e183-f424-e053-dadaa90a57ce	Allergy Attack Relief to Go ™
51596-009-05	2020-01-31	C162847	48780-1	9d75b9cf-e183-f424-e053-dadaa90a57ce	Allergy Attack Relief to Go ™
51596-009-10	2020-01-31	C162847	48780-1	9d75b9cf-e183-f424-e053-dadaa90a57ce	Allergy Attack Relief to Go ™
51596-009-12	2020-01-31	C162847	48780-1	9d75b9cf-e183-f424-e053-dadaa90a57ce	Allergy Attack Relief to Go ™
51596-009-24	2020-01-31	C162847	48780-1	9d75b9cf-e183-f424-e053-dadaa90a57ce	Allergy Attack Relief to Go ™

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	SPL version
51596-009-01	Allergy Attack Relief to Go	1 in 1 POUCH	POWDER	1	4
51596-009-05	Allergy Attack Relief to Go	5 in 1 BOX	POWDER	5	4
51596-009-10	Allergy Attack Relief to Go	10 in 1 BOX	POWDER	10	4
51596-009-10	Allergy Attack Relief to Go	1 in 1 PACKET	POWDER	1	4
51596-009-12	Allergy Attack Relief to Go	1 in 1 POUCH	POWDER	1	4
51596-009-12	Allergy Attack Relief to Go	12 in 1 BOX	POWDER	12	4
51596-009-24	Allergy Attack Relief to Go	24 in 1 BOX	POWDER	24	4
51596-009-24	Allergy Attack Relief to Go	1 in 1 POUCH	POWDER	1	4

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
51596-009	ALLERGY ATTACK RELIEF TO GO (DIPHENHYDRAMINE HYDROCHLORIDE) POWDER [BREAKTHROUGH PRODUCTS INC.]	4	Legacy NDC, 8 package rows	20141017_2da1341d-5c2d-47ef-8498-f58fbb4f6300.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	SPL version
DIPHENHYDRAMINE HYDROCHLORIDE	ACTIVE INGREDIENT	TC2D6JAD40	4
DIPHENHYDRAMINE	ACTIVE MOIETY	8GTS82S83M	4
anhydrous citric acid	INACTIVE INGREDIENT	XF417D3PSL	4
dextrose	INACTIVE INGREDIENT	IY9XDZ35W2	4
ETHYLCELLULOSES	INACTIVE INGREDIENT	7Z8S9VYZ4B	4
HYDROXYPROPYL CELLULOSE (TYPE H)	INACTIVE INGREDIENT	RFW2ET671P	4
sucralose	INACTIVE INGREDIENT	96K6UQ3ZD4	4
sucrose	INACTIVE INGREDIENT	C151H8M554	4

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

Allergy Attack Relief to Go
DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE
anhydrous citric acid
ETHYLCELLULOSES
dextrose
HYDROXYPROPYL CELLULOSE (TYPE H)
sucralose
sucrose

NDC Codes#

Product NDC, Package NDC table
Product NDC	Package NDC
51596-009	51596-009-10, 51596-009-01, 51596-009-05, 51596-009-12, 51596-009-24

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 7 matching rows.

Name, UNII, Kind table
Name	UNII	Kind
DIPHENHYDRAMINE HYDROCHLORIDE	TC2D6JAD40	ACTIB
anhydrous citric acid	XF417D3PSL	IACT
ETHYLCELLULOSES	7Z8S9VYZ4B	IACT
dextrose	IY9XDZ35W2	IACT
HYDROXYPROPYL CELLULOSE (TYPE H)	RFW2ET671P	IACT
sucralose	96K6UQ3ZD4	IACT
sucrose	C151H8M554	IACT

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 4 · 193 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredient	IID ingredient	UNII	Dosage form / route	Potency	Maximum daily exposure	Match
sucrose	SUCROSE	C151H8M554	CAPSULE / ORAL		3568 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
sucrose	SUCROSE	C151H8M554	TABLET / SUBLINGUAL	109 mg		Exact identifier — unii candidate 48 equally ranked IID candidates
sucrose	SUCROSE	C151H8M554	TABLET, DELAYED RELEASE / ORAL	295.33 mg		Exact identifier — unii candidate 48 equally ranked IID candidates
anhydrous citric acid	ANHYDROUS CITRIC ACID	XF417D3PSL	SYRUP / ORAL		268 mg	Exact identifier — unii candidate 61 equally ranked IID candidates
anhydrous citric acid	ANHYDROUS CITRIC ACID	XF417D3PSL	POWDER, FOR SOLUTION / ORAL		123 mg	Exact identifier — unii candidate 61 equally ranked IID candidates
ETHYLCELLULOSES	ETHYLCELLULOSE	7Z8S9VYZ4B	SUSPENSION, EXTENDED RELEASE / ORAL	NA		Exact identifier — unii candidate 14 equally ranked IID candidates
dextrose	DEXTROSE	IY9XDZ35W2	CONCENTRATE / ORAL	400 mg		Exact identifier — unii candidate 21 equally ranked IID candidates
anhydrous citric acid	ANHYDROUS CITRIC ACID	XF417D3PSL	FILM / BUCCAL		9 mg	Exact identifier — unii candidate 61 equally ranked IID candidates
dextrose	DEXTROSE	IY9XDZ35W2	INJECTION / INTRAMUSCULAR	5 %w/v		Exact identifier — unii candidate 21 equally ranked IID candidates
sucrose	SUCROSE	C151H8M554	POWDER, FOR SUSPENSION / ORAL		40017 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
HYDROXYPROPYL CELLULOSE (TYPE H)	HYDROXYPROPYL CELLULOSE (1600000 WAMW)	RFW2ET671P	FILM / BUCCAL		87 mg	Exact identifier — unii candidate 27 equally ranked IID candidates
HYDROXYPROPYL CELLULOSE (TYPE H)	HYDROXYPROPYL CELLULOSE (1600000 WAMW)	RFW2ET671P	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL	39.2 mg		Exact identifier — unii candidate 27 equally ranked IID candidates
anhydrous citric acid	ANHYDROUS CITRIC ACID	XF417D3PSL	SUSPENSION/ DROPS / OPHTHALMIC	0.05 %w/v		Exact identifier — unii candidate 61 equally ranked IID candidates
sucralose	SUCRALOSE	96K6UQ3ZD4	FILM, SOLUBLE / ORAL		33 mg	Exact identifier — unii candidate 22 equally ranked IID candidates
anhydrous citric acid	ANHYDROUS CITRIC ACID	XF417D3PSL	INJECTION, SOLUTION / INTRAMUSCULAR		25 mg	Exact identifier — unii candidate 61 equally ranked IID candidates
anhydrous citric acid	ANHYDROUS CITRIC ACID	XF417D3PSL	LOTION / TOPICAL		211 mg	Exact identifier — unii candidate 61 equally ranked IID candidates
sucralose	SUCRALOSE	96K6UQ3ZD4	TABLET, ORALLY DISINTEGRATING / ORAL		60 mg	Exact identifier — unii candidate 22 equally ranked IID candidates
ETHYLCELLULOSES	ETHYLCELLULOSE	7Z8S9VYZ4B	CAPSULE / ORAL	12.32 mg		Exact identifier — unii candidate 14 equally ranked IID candidates
sucrose	SUCROSE	C151H8M554	LOZENGE / BUCCAL	NA		Exact identifier — unii candidate 48 equally ranked IID candidates
sucrose	SUCROSE	C151H8M554	INJECTION / SUBCUTANEOUS	47.75 mg		Exact identifier — unii candidate 48 equally ranked IID candidates
anhydrous citric acid	ANHYDROUS CITRIC ACID	XF417D3PSL	LIQUID / INTRAVENOUS		18 mg	Exact identifier — unii candidate 61 equally ranked IID candidates
sucrose	SUCROSE	C151H8M554	DROPS / ORAL	NA		Exact identifier — unii candidate 48 equally ranked IID candidates
sucrose	SUCROSE	C151H8M554	INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS	900 mg		Exact identifier — unii candidate 48 equally ranked IID candidates
ETHYLCELLULOSES	ETHYLCELLULOSE	7Z8S9VYZ4B	TABLET, EXTENDED RELEASE / ORAL		1120 mg	Exact identifier — unii candidate 14 equally ranked IID candidates
sucrose	SUCROSE	C151H8M554	POWDER / ORAL		27768 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
anhydrous citric acid	ANHYDROUS CITRIC ACID	XF417D3PSL	TABLET, CHEWABLE, EXTENDED RELEASE / ORAL		12 mg	Exact identifier — unii candidate 61 equally ranked IID candidates
HYDROXYPROPYL CELLULOSE (TYPE H)	HYDROXYPROPYL CELLULOSE (1600000 WAMW)	RFW2ET671P	POWDER / ORAL		244 mg	Exact identifier — unii candidate 27 equally ranked IID candidates
HYDROXYPROPYL CELLULOSE (TYPE H)	HYDROXYPROPYL CELLULOSE (1600000 WAMW)	RFW2ET671P	SUSPENSION / ORAL		100 mg	Exact identifier — unii candidate 27 equally ranked IID candidates
sucrose	SUCROSE	C151H8M554	SOLUTION / RECTAL	35.42 %w/v		Exact identifier — unii candidate 48 equally ranked IID candidates
anhydrous citric acid	ANHYDROUS CITRIC ACID	XF417D3PSL	FILM / SUBLINGUAL		11 mg	Exact identifier — unii candidate 61 equally ranked IID candidates
sucrose	SUCROSE	C151H8M554	TABLET / ORAL		4249 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
ETHYLCELLULOSES	ETHYLCELLULOSE	7Z8S9VYZ4B	TABLET, COATED / ORAL	20 mg		Exact identifier — unii candidate 14 equally ranked IID candidates
ETHYLCELLULOSES	ETHYLCELLULOSE	7Z8S9VYZ4B	TABLET, DELAYED RELEASE / ORAL	53.8 mg		Exact identifier — unii candidate 14 equally ranked IID candidates
HYDROXYPROPYL CELLULOSE (TYPE H)	HYDROXYPROPYL CELLULOSE (1600000 WAMW)	RFW2ET671P	TABLET, FILM COATED, EXTENDED RELEASE / ORAL	187.6 mg		Exact identifier — unii candidate 27 equally ranked IID candidates
sucrose	SUCROSE	C151H8M554	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS		308 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
anhydrous citric acid	ANHYDROUS CITRIC ACID	XF417D3PSL	CLOTH / TOPICAL	4.2 mg		Exact identifier — unii candidate 61 equally ranked IID candidates
anhydrous citric acid	ANHYDROUS CITRIC ACID	XF417D3PSL	INJECTION / INTRAVENOUS		1152 mg	Exact identifier — unii candidate 61 equally ranked IID candidates
dextrose	DEXTROSE	IY9XDZ35W2	TABLET / ORAL	183.66 mg		Exact identifier — unii candidate 21 equally ranked IID candidates
anhydrous citric acid	ANHYDROUS CITRIC ACID	XF417D3PSL	SHAMPOO / TOPICAL	0.07 %w/w		Exact identifier — unii candidate 61 equally ranked IID candidates
HYDROXYPROPYL CELLULOSE (TYPE H)	HYDROXYPROPYL CELLULOSE (1600000 WAMW)	RFW2ET671P	TABLET / ORAL		230 mg	Exact identifier — unii candidate 27 equally ranked IID candidates
sucrose	SUCROSE	C151H8M554	INJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS		1 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
sucralose	SUCRALOSE	96K6UQ3ZD4	GRANULE / ORAL	5.4 mg		Exact identifier — unii candidate 22 equally ranked IID candidates
sucrose	SUCROSE	C151H8M554	INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS	9.4 %w/v		Exact identifier — unii candidate 48 equally ranked IID candidates
anhydrous citric acid	ANHYDROUS CITRIC ACID	XF417D3PSL	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL		48 mg	Exact identifier — unii candidate 61 equally ranked IID candidates
sucrose	SUCROSE	C151H8M554	GRANULE, FOR SOLUTION / ORAL		42596 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
sucralose	SUCRALOSE	96K6UQ3ZD4	TABLET, EFFERVESCENT / ORAL		1080 mg	Exact identifier — unii candidate 22 equally ranked IID candidates
HYDROXYPROPYL CELLULOSE (TYPE H)	HYDROXYPROPYL CELLULOSE (1600000 WAMW)	RFW2ET671P	CAPSULE / ORAL		120 mg	Exact identifier — unii candidate 27 equally ranked IID candidates
HYDROXYPROPYL CELLULOSE (TYPE H)	HYDROXYPROPYL CELLULOSE (1600000 WAMW)	RFW2ET671P	GEL / TRANSDERMAL		20 mg	Exact identifier — unii candidate 27 equally ranked IID candidates
HYDROXYPROPYL CELLULOSE (TYPE H)	HYDROXYPROPYL CELLULOSE (1600000 WAMW)	RFW2ET671P	TABLET, COATED / ORAL	13.6 mg		Exact identifier — unii candidate 27 equally ranked IID candidates
sucrose	SUCROSE	C151H8M554	POWDER, FOR SOLUTION / ORAL		38666 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
HYDROXYPROPYL CELLULOSE (TYPE H)	HYDROXYPROPYL CELLULOSE (1600000 WAMW)	RFW2ET671P	GEL / TOPICAL		222 mg	Exact identifier — unii candidate 27 equally ranked IID candidates
anhydrous citric acid	ANHYDROUS CITRIC ACID	XF417D3PSL	SPRAY / TOPICAL	0.01 %w/w		Exact identifier — unii candidate 61 equally ranked IID candidates
HYDROXYPROPYL CELLULOSE (TYPE H)	HYDROXYPROPYL CELLULOSE (1600000 WAMW)	RFW2ET671P	TABLET, DELAYED RELEASE / ORAL		450 mg	Exact identifier — unii candidate 27 equally ranked IID candidates
sucralose	SUCRALOSE	96K6UQ3ZD4	TABLET, CHEWABLE / ORAL		28 mg	Exact identifier — unii candidate 22 equally ranked IID candidates
sucrose	SUCROSE	C151H8M554	CONCENTRATE / ORAL		4800 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
sucrose	SUCROSE	C151H8M554	INJECTION / INTRAVENOUS		1950 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
HYDROXYPROPYL CELLULOSE (TYPE H)	HYDROXYPROPYL CELLULOSE (1600000 WAMW)	RFW2ET671P	CAPSULE, COATED PELLETS / ORAL	41.4 mg		Exact identifier — unii candidate 27 equally ranked IID candidates
sucrose	SUCROSE	C151H8M554	SYRUP / ORAL		46400 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
ETHYLCELLULOSES	ETHYLCELLULOSE	7Z8S9VYZ4B	SYSTEM / TOPICAL		10 mg	Exact identifier — unii candidate 14 equally ranked IID candidates
sucrose	SUCROSE	C151H8M554	SOLUTION / ORAL		70000 mg	Exact identifier — unii candidate 48 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
8ffb4f55-f838-4a59-8894-158acb12af74			2da1341d-5c2d-47ef-8498-f58fbb4f6300	2014-10-09	Warnings	Exact identifier spl id: 8ffb4f55-f838-4a59-8894-158acb12af74 spl set id: 2da1341d-5c2d-47ef-8498-f58fbb4f6300

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.